CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Income Statement [Abstract]
Net revenues	$ 154,994	$ 138,503	$ 605,220
Cost of revenues	38,521	33,689	137,181
Gross profit	116,473	104,814	468,039
Operating costs and expenses:
Research, development and clinical studies	53,777	51,598	209,645
Sales and marketing	55,792	55,206	239,063
General and administrative	44,769	39,530	189,827
Total operating costs and expenses	154,338	146,334	638,535
Operating income (loss)	(37,865)	(41,520)	(170,496)
Financial income (expenses), net	7,570	9,878	39,334
Income (loss) before income tax	(30,295)	(31,642)	(131,162)
Income tax	4,024	7,118	37,465
Net income (loss)	$ (34,319)	$ (38,760)	$ (168,627)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.31)	$ (0.36)	$ (1.56)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.31)	$ (0.36)	$ (1.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	110,281,832	107,266,198	107,834,368
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	110,281,832	107,266,198	107,834,368